Despite Early Promise GLP-1 Disappoints in Parkinson’s
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 study suggesting a potential role for GLP-1 agonists in PD.
Medscape Medical News
source https://www.medscape.com/viewarticle/despite-early-promise-glp-1-disappoints-parkinsons-disease-2025a1000325?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/despite-early-promise-glp-1-disappoints-parkinsons-disease-2025a1000325?src=rss
Comments
Post a Comment